David T Yeung

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text

Medicine, Oncology, Pharmacology +9

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

Adrian Bloor, Amit Patel, James E. Griffin et al. · Nature Medicine · 2020 · 289 citations

Life Sciences, Biotechnology, Translational Sciences +14

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Susan Branford, Paul Wang, David T Yeung et al. · Blood · 2018 · 209 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Susan Branford, David T Yeung, Wendy T Parker et al. · Blood · 2014 · 198 citations

Medicine, Hematology, Oncology +8